ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Severine Vermeire  ¹     Bruce E. Sands  ²     Sophie Biguenet  ³     Hartmut Ehrlich     Paul GINESTE     Josianne Nitcheu     William Sandborn  ^4    
1 University Hospitals Leuven, Leuven, Belgium
² Icahn School of Medicine at Mount Sinai, New York, United States
³ Abivax, Paris, France
⁴ University of California San Diego, San Diego, United States

Session
Clinical trials in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)